# ORI Capital

ORI Capital is a Venture Capital based in Hong Kong, Hong Kong.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Hong Kong, Hong Kong
- **Region:** Asia
- **Address:** Hong Kong, Hong Kong
- **Founded:** 2015
- **Assets under management:** Undisclosed
- **Website:** ori-capital.com
- **LinkedIn:** https://www.linkedin.com/company/oricapital

## Regulatory record

- **Reports private funds:** No

## About

ORI Capital is a venture capital firm that invests in healthcare technology companies worldwide. It has made 10 investments, including a Series E investment in CG Oncology on November 15, 2022. The firm has facilitated 4 portfolio exits, with CG Oncology being its most recent exit on January 25, 2024.

## Sectors

- Digital Health
- Healthcare Services

## People

- Simone Song — Founder & Senior Partner

## Questions

### How does ORI Capital source proprietary deal flow?

ORI Capital employs a dedicated data science team — including a Vice President, data engineers, and analysts — to screen scientific literature, patent databases, and clinical-trial registries using proprietary machine-learning tools. This in-house capability functions as an AI-driven origination engine, designed to identify therapeutic and diagnostic assets before they appear on conventional VC radars.

### What therapeutic areas does ORI Capital focus on?

The firm targets diagnostics, drug delivery, and therapeutics across the three disease categories with the highest global mortality rates: cancer, cardiovascular disease, and neurodegenerative conditions. Its website does not indicate investment in platform biotech tools or non-therapeutic health IT.

## Related profiles

- [Oria Capital](https://altss.com/profile/oria-capital)
- [Oridun Capital Management](https://altss.com/profile/oridun-capital-management)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/ori-capital

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology